
On politicians…


President Joe Biden’s communications staff have made efforts to find out what reporters will ask White House press secretary Jen Psaki ahead of press briefings, according to a report from the Daily Beast.
This has raised concerns from some members of the press and the issue was reportedly recently discussed during a recent informal White House Correspondents Association (WHCA) call, according to the publication.
WHCA leaders reportedly told reporters present at the virtual meeting to either push back on or ignore inquires from the administration regarding this matter. The White House’s alleged efforts, though, “pissed off enough reporters for people to flag it for the [WHCA] for them to deal with it,” one source told the Daily Beast.
“While it’s a relief to see briefings return, particularly with a commitment to factual information, the press can’t really do its job in the briefing room if the White House is picking and choosing the questions they want,” a White House correspondent said according to the report.


While millions of Americans wait for the COVID-19 vaccine, hospital board members, their trustees and donors around the country have gotten early access to the scarce drug or offers for vaccinations, raising complaints about favoritism tainting decisions about who gets inoculated and when.
In Rhode Island, Attorney General Peter Neronha opened an inquiry after reports that two hospital systems offered their board members vaccinations. A Seattle-area hospital system was rebuked by Washington Gov. Jay Inslee after it offered COVID-19 vaccination appointments to major donors. And in Kansas, members of a hospital board received vaccinations during the first phase of the state’s rollout, which was intended for people at greater risk for infection.
Hospitals in Florida, New Jersey and Virginia also have faced questions about distributing vaccines, including to donors, trustees and relatives of executives.
The disclosures could threaten public confidence in a national rollout already marked by vaccine shortages, appointment logjams and inconsistent standards state to state for determining who’s eligible.
The Securities and Exchange Commission broke its silence Friday morning on the populist investor uprising that has sent the stock price of beleaguered retailer GameStop “to the moon,”warning everyone involved that they are watching… and, for the time being, not doing a whole lot else, it seems.
“The Commission will closely review actions taken by regulated entities that may disadvantage investors or otherwise unduly inhibit their ability to trade certain securities,” the joint statement from acting SEC Chair Allison Herren Lee and the three commissioners.
“I am unable to accept the idea that I should be an obedient subject of a gang of corrupt, unprincipled thugs who pontificate about freedom while enslaving the population.”
John Pugsley
Big Pharma did not like Donald Trump, but they certainly like Joe Biden – especially now.
In an ongoing frenzy to undo everything Trump did over the last four years, Joe Biden froze a December rule aimed at lowering prescription drug prices for insulin and epinephrine.
On Thursday, Biden’s Department of Health and Human Services announced the new rule would be put on hold, along with several other Trump-era orders pending a 60 day review, The Federalist reports. Biden Chief of Staff Ron Klain directed federal agencies on Wednesday to pause orders that had been signed and published by Trump’s administration but not yet effective.
In December, 2020 Trump ordered community health centers deliver savings and discounts to low-income patients for the purchase of insulin and epinephrine in efforts to make high drug costs more affordable. Insulin is used to treat diabetes, which more than 20 million Americans struggle with every day, while epinephrine is used to treat allergic reactions.
Big Pharma hated Trump because one of his campaign promises was lowering the prices of important pharmaceutical drugs, which he tackled during his term. Trump’s “most favored nation” law aimed to lower prices in Medicare by linking the costs of certain medicines to cheaper prices in other developed countries. Obviously, Big Pharma strongly opposed the measure, arguing it would limit access.
The big three insulin producers are Eli Lilly and Company, Novo Nordisk A/S, and Sanofi S.A., in which they dominate more than 90% of the world insulin market by value, SWFI reports.
Indeed, these three companies will benefit greatly from the freeze.
Interestingly enough, during the 2020 election cycle Eli Lilly gave $138,880 to Joe Biden. Perhaps he is just returning the favor.
Biden has faced much scrutiny after the freeze, many wondering what is the point?


You must be logged in to post a comment.